The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Liver most cancers stays a major international well being problem and may develop silently in sufferers who're unaware they've underlying liver illness....
The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation (ODD) to zavabresib (previously OPN-2853), an investigational remedy for the...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to an investigational CAR-T cell remedy, soficabtagene geleucel (Sofi-cel), for...
Sufferers with Waldenström Non-Hodgkin lymphoma within the U.S. achieved sturdy full responses of as much as 15 months utilizing a chemotherapy-free CD19...
Throughout the 2026 ASCO Gastrointestinal (GI) Cancers Symposium, CURE was stay on website, the place we spoke immediately with conferencegoers, oncologists and...
